Revolution Medicines D
D
RVMD
172.280
USD
-4.01
(-2.27%)
Post Trading·172.020USD-0.260(-0.15%)
Last updated: · Delayed 15 min
Revolution Medicines operating income 2017–2026What are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
Revolution Medicines's operating income in Q3 FY2026, the three months to 30 September 2026, was -373.15M USD, against a loss of 315.27M USD on the same quarter a year before. Revolution Medicines's operating income in fiscal year 2025 was -1.18B USD, against a loss of 689.52M USD on the year before.
Last updated 8 Nov 2026 · Next report 24 Feb 2027
Operating income
Operating income Operating margin
| Fiscal year | Period ending | Operating income | Growth | Operating margin | Gross profit | Gross margin | EBITDA |
|---|---|---|---|---|---|---|---|
| TTM | 30 Sept 2026 | -1.69B | — | — | — | — | -1.77B |
| FY2025 | 31 Dec 2025 | -1.18B | — | — | -16.56M | — | -1.09B |
| FY2024 | 31 Dec 2024 | -689.52M | — | — | 0.00 | — | -589.02M |
| FY2023 | 31 Dec 2023 | -487.19M | — | -4,207.12% | 11.58M | 100.00% | -430.28M |
| FY2022 | 31 Dec 2022 | -258.28M | — | -730.01% | 35.38M | 100.00% | -239.47M |
| FY2021 | 31 Dec 2021 | -188.01M | — | -639.70% | 29.39M | 100.00% | -179.75M |
| FY2020 | 31 Dec 2020 | -110.70M | — | -257.54% | 42.98M | 100.00% | -101.91M |
| FY2019 | 31 Dec 2019 | -54.12M | — | -108.15% | 50.04M | 100.00% | -48.59M |
| FY2018 | 31 Dec 2018 | -40.33M | — | -200.00% | 20.17M | 100.00% | -39.91M |
| FY2017 | 31 Dec 2017 | -31.13M | — | — | -26.59M | — | -29.84M |
| Quarter | Period ending | Operating income | Growth on a year before | Operating margin | Gross profit | Gross margin | EBITDA |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | -373.15M | — | -188.88% | 197.23M | 99.83% | -373.05M |
| Q2 FY2026 | 30 Jun 2026 | -505.13M | — | — | 0.00 | — | -616.09M |
| Q1 FY2026 | 31 Mar 2026 | -445.22M | — | — | -4.54M | — | -437.08M |
| Q4 FY2025 | 31 Dec 2025 | -361.63M | — | — | -4.70M | — | -348.25M |
| Q3 FY2025 | 30 Sept 2025 | -315.27M | — | — | 0.00 | — | -289.44M |
| Q2 FY2025 | 30 Jun 2025 | -264.71M | — | — | 0.00 | — | -243.99M |
| Q1 FY2025 | 31 Mar 2025 | -240.76M | — | — | 0.00 | — | -209.70M |
| Q4 FY2024 | 31 Dec 2024 | -216.31M | — | — | 0.00 | — | -191.94M |
| Q3 FY2024 | 30 Sept 2024 | -175.71M | — | — | 0.00 | — | -153.41M |
| Q2 FY2024 | 30 Jun 2024 | -156.64M | — | — | 0.00 | — | -130.44M |
| Q1 FY2024 | 31 Mar 2024 | -140.86M | — | — | 0.00 | — | -113.24M |
| Q4 FY2023 | 31 Dec 2023 | — | — | — | — | — | — |
| Q3 FY2023 | 30 Sept 2023 | -123.25M | — | — | 0.00 | — | -110.16M |
| Q2 FY2023 | 30 Jun 2023 | — | — | — | — | — | — |
| Q1 FY2023 | 31 Mar 2023 | — | — | — | — | — | — |
| Q4 FY2022 | 31 Dec 2022 | — | — | — | — | — | — |
| Q3 FY2022 | 30 Sept 2022 | — | — | — | — | — | — |
| Q2 FY2022 | 30 Jun 2022 | — | — | — | — | — | — |
| Q1 FY2022 | 31 Mar 2022 | — | — | — | — | — | — |
| Q4 FY2021 | 31 Dec 2021 | — | — | — | — | — | — |
| Q3 FY2021 | 30 Sept 2021 | — | — | — | — | — | — |
| Q2 FY2021 | 30 Jun 2021 | — | — | — | — | — | — |
| Q1 FY2021 | 31 Mar 2021 | — | — | — | — | — | — |
| Q4 FY2020 | 31 Dec 2020 | — | — | — | — | — | — |
| Q3 FY2020 | 30 Sept 2020 | — | — | — | — | — | — |
| Q2 FY2020 | 30 Jun 2020 | — | — | — | — | — | — |
| Q1 FY2020 | 31 Mar 2020 | — | — | — | — | — | — |
| Q4 FY2019 | 31 Dec 2019 | — | — | — | — | — | — |
| Q3 FY2019 | 30 Sept 2019 | — | — | — | — | — | — |
| Q2 FY2019 | 30 Jun 2019 | — | — | — | — | — | — |
| Q1 FY2019 | 31 Mar 2019 | — | — | — | — | — | — |
| Q4 FY2018 | 31 Dec 2018 | — | — | — | — | — | — |
Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.
See also:Revenue,Net income,EPS,Shares outstanding,Cash on hand,Total debt,Free cash flow,Income statement
Common questions about Revolution Medicines's operating income
Source: Financial Modeling PrepVerified against SEC filings